Immune Responses to Revaccination After Potentially Insufficient Priming With the Japanese Encephalitis Vaccine IXIARO Batch JEC09L37.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2013
At a glance
- Drugs IC 51 (Primary)
- Indications Japanese encephalitis
- Focus Pharmacodynamics
- Sponsors Intercell
- 01 Mar 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 27 Mar 2012 New trial record